Ferroglobe Reports Third Quarter Results of 2019
Ferroglobe Reports Third Quarter Results of 2019
Sales of
- Q3 sales of
$381.7 million , compared to$409.5 million in Q2 2019 and$524.4 million in Q3 2018 - Q3 net loss of
$(140.1) million compared to a net loss of$(43.7) million in Q2 2019 and a net loss of$(2.9) million in Q3 2018, with the Q3 2019 net loss including a goodwill impairment charge of$174.0 million - Q3 adjusted net loss attributable to Parent of
$(16.1) million compared to a net loss of$(22.2) million in Q2 2019 and a net loss of$(0.1) million in Q3 2018 - Q3 adjusted EBITDA of
$(7.2) million compared to$5.0 million in Q2 2019 and$43.9 million in Q3 2018 - Successful closing of the divestiture of FerroAtlántica, S.A.U. on
August 30, 2019 , resulting in gross proceeds of$171.2 million and a profit on disposal of$80.7 million - Successful closing of a new, five-year
$100 million North American asset-based revolving credit facility onOctober 11, 2019 and repayment of the Company’s previous revolving credit facility - Further operational changes announced to the global production platform in an effort to streamline operations, adapting production to reduced demand and decreasing inventory levels
Earnings Highlights
In Q3 2019,
Q3 2019 reported EBITDA was
Quarter Ended | Quarter Ended | Quarter Ended | Nine Months Ended | Nine Months Ended | ||||||||||||||||
$,000 (unaudited) | September 30, 2019 | June 30, 2019 | September 30, 2018 * | September 30, 2019 | September 30, 2018 * | |||||||||||||||
Sales | $ | 381,745 | $ | 409,479 | $ | 524,407 | $ | 1,238,615 | $ | 1,650,950 | ||||||||||
Net (loss) profit | $ | (140,139 | ) | $ | (43,658 | ) | $ | (2,916 | ) | $ | (212,351 | ) | $ | 98,728 | ||||||
Diluted EPS | $ | (0.83 | ) | $ | (0.24 | ) | $ | (0.01 | ) | $ | (1.23 | ) | $ | 0.60 | ||||||
Adjusted net (loss) income attributable to the parent | $ | (16,085 | ) | $ | (22,221 | ) | $ | (135 | ) | $ | (60,200 | ) | $ | 59,189 | ||||||
Adjusted diluted EPS | $ | (0.10 | ) | $ | (0.13 | ) | $ | (0.00 | ) | $ | (0.36 | ) | $ | 0.34 | ||||||
Adjusted EBITDA | $ | (7,210 | ) | $ | 5,035 | $ | 43,864 | $ | 1,152 | $ | 206,867 | |||||||||
Adjusted EBITDA margin | -1.9 | % | 1.2 | % | 8.4 | % | 0.1 | % | 12.5 | % |
* The amounts for prior periods have been restated to reflect the impact of the profit / (loss) from discontinued operations associated with the sale of the Company’s Spanish hydroelectric plants
Cash Flow and Balance Sheet
Cash used in operations during Q3 2019 was $82.3 million, including a
Working capital increased from
Net debt was
Following a review of the carrying value of the Company’s assets as of
Beatriz García-Cos, Ferroglobe’s Chief Financial Officer commented, “The entire management team is committed to returning the Company to profitability and delivering a healthier liquidity position and stronger balance sheet. The operational changes support the financial strategy and will help us achieve these goals.”
Successful closing of non-core asset divestitures
FerroAtlántica, S.A.U.
On
Ultracore Polska ZOO
On
Timberlands in
On
Other recent developments
On
Most recently the Company has undertaken an extended outage at its Mo I Rana facility in
In the aggregate these measures will reduce the Company’s immediate production capacity across all major product categories. With these operational changes, Ferroglobe’s current silicon metal capacity (annualized run-rate) will decline to 186,000 tons, down 56,000 tons from 242,000 tons at the end of Q3 2019. Silicon-based alloys capacity will decline to 354,000 tons, down 88,000 tons from 442,000 tons at the end of Q3 2019. Lastly, the Company’s manganese-based alloys capacity will decline to 538,000 tons, down 125,000 tons from 663,000 tons at the end of Q3 2019.
On
Discussion of Third Quarter 2019 Results
Sales
Sales for Q3 2019 were
Quarter Ended | Quarter Ended | Quarter Ended | Nine Months Ended | Nine Months Ended | ||||||||||||||||||||
September 30, 2019 | June 30, 2019 | Change | September 30, 2018 | Change | September 30, 2019 | September 30, 2018 | Change | |||||||||||||||||
Shipments in metric tons: | ||||||||||||||||||||||||
Silicon Metal | 60,225 | 54,084 | 11.4 | % | 81,686 | -26.3 | % | 176,578 | 259,214 | -31.9 | % | |||||||||||||
Silicon-based Alloys | 69,879 | 79,264 | -11.8 | % | 75,964 | -8.0 | % | 230,944 | 230,506 | 0.2 | % | |||||||||||||
Manganese-based Alloys | 93,996 | 99,555 | -5.6 | % | 98,280 | -4.4 | % | 297,221 | 276,913 | 7.3 | % | |||||||||||||
Total shipments* | 224,100 | 232,903 | -3.8 | % | 255,930 | -12.4 | % | 704,743 | 766,633 | -8.1 | % | |||||||||||||
Average selling price ($/MT): | ||||||||||||||||||||||||
Silicon Metal | $ | 2,175 | $ | 2,320 | -6.3 | % | $ | 2,636 | -17.5 | % | $ | 2,284 | $ | 2,726 | -16.2 | % | ||||||||
Silicon-based Alloys | $ | 1,490 | $ | 1,572 | -5.2 | % | $ | 1,802 | -17.3 | % | $ | 1,582 | $ | 1,889 | -16.3 | % | ||||||||
Manganese-based Alloys | $ | 1,140 | $ | 1,188 | -4.0 | % | $ | 1,211 | -5.9 | % | $ | 1,167 | $ | 1,289 | -9.5 | % | ||||||||
Total* | $ | 1,527 | $ | 1,582 | -3.5 | % | $ | 1,841 | -17.1 | % | $ | 1,583 | $ | 1,955 | -19.0 | % | ||||||||
Average selling price ($/lb.): | ||||||||||||||||||||||||
Silicon Metal | $ | 0.99 | $ | 1.05 | -6.3 | % | $ | 1.20 | -17.5 | % | $ | 1.04 | $ | 1.24 | -16.2 | % | ||||||||
Silicon-based Alloys | $ | 0.68 | $ | 0.71 | -5.2 | % | $ | 0.82 | -17.3 | % | $ | 0.72 | $ | 0.86 | -16.3 | % | ||||||||
Manganese-based Alloys | $ | 0.52 | $ | 0.54 | -4.0 | % | $ | 0.55 | -5.9 | % | $ | 0.53 | $ | 0.58 | -9.5 | % | ||||||||
Total* | $ | 0.69 | $ | 0.72 | -3.5 | % | $ | 0.84 | -17.1 | % | $ | 0.72 | $ | 0.89 | -19.0 | % |
* Excludes by-products and other
Sales Prices & Volumes By Product
During Q3 2019, total product average selling prices decreased by 3.5% versus Q2 2019. Q3 average selling prices of silicon metal decreased 6.3%, silicon-based alloys decreased 5.2%, and manganese-based alloys decreased 4.0%. Sales volumes in Q3 declined by 3.8% versus the prior quarter. Q3 sales volumes of silicon metal increased 11.4%, silicon-based alloys decreased 11.8%, and manganese-based alloys decreased 5.6% versus Q2 2019.
Cost of Sales
Cost of sales was
Other Operating Expenses
Other operating expenses was
Net Loss Attributable to the Parent
In Q3 2019, net loss attributable to the Parent was
Adjusted EBITDA
In Q3 2019, adjusted EBITDA was
Conference Call
Ferroglobe management will review the third quarter results of 2019 during a conference call at 9:00 a.m. Eastern Time on December 3, 2019.
The dial-in number for participants in the United States is 877‑293‑5491 (conference ID 5768864). International callers should dial +1 914‑495‑8526 (conference ID 5768864). Please dial in at least five minutes prior to the call to register. The call may also be accessed via an audio webcast available at https://edge.media-server.com/mmc/p/8nkuu92x.
About Ferroglobe
Ferroglobe is one of the world’s leading suppliers of silicon metal, silicon-based and manganese-based specialty alloys and other ferroalloys, serving a customer base across the globe in dynamic and fast-growing end markets, such as solar, automotive, consumer products, construction and energy. The Company is based in London. For more information, visit http://investor.ferroglobe.com.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of U.S. securities laws. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe the Company’s future plans, strategies and expectations. Forward-looking statements often use forward-looking terminology, including words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “forecast”, “guidance”, “intends”, “likely”, “may”, “plan”, “potential”, “predicts”, “seek”, “target”, “will” and words of similar meaning or the negative thereof.
Forward-looking statements contained in this press release are based on information currently available to the Company and assumptions that management believe to be reasonable, but are inherently uncertain. As a result, Ferroglobe’s actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company’s control.
Forward-looking financial information and other metrics presented herein represent the Company’s goals and are not intended as guidance or projections for the periods referenced herein or any future periods.
All information in this press release is as of the date of its release. Ferroglobe does not undertake any obligation to update publicly any of the forward-looking statements contained herein to reflect new information, events or circumstances arising after the date of this press release. You should not place undue reliance on any forward-looking statements, which are made only as of the date of this press release.
Non-IFRS Measures
Adjusted EBITDA, adjusted EBITDA margin, adjusted net profit, adjusted profit per share, working capital and net debt, are non-IFRS financial metrics that, we believe, are pertinent measures of Ferroglobe’s success.
INVESTOR CONTACT:
EVP – Investor Relations
Email: investor.relations@ferroglobe.com
Unaudited Condensed Consolidated Income Statement
(in thousands of U.S. dollars, except per share amounts)
Quarter Ended | Quarter Ended | Quarter Ended | Nine Months Ended | Nine Months Ended | ||||||||||||||||
September 30, 2019 | June 30, 2019 | September 30, 2018* | September 30, 2019 | September 30, 2018* | ||||||||||||||||
Sales | $ | 381,745 | $ | 409,479 | $ | 524,407 | $ | 1,238,615 | $ | 1,650,950 | ||||||||||
Cost of sales | (277,692 | ) | (292,432 | ) | (334,340 | ) | (899,492 | ) | (998,629 | ) | ||||||||||
Other operating income | 13,215 | 14,530 | 5,630 | 41,766 | 20,925 | |||||||||||||||
Staff costs | (72,536 | ) | (74,852 | ) | (88,134 | ) | (221,651 | ) | (258,206 | ) | ||||||||||
Other operating expense | (50,060 | ) | (62,924 | ) | (63,920 | ) | (166,901 | ) | (207,223 | ) | ||||||||||
Depreciation and amortization charges, operating allowances and write-downs | (29,591 | ) | (30,204 | ) | (29,587 | ) | (90,165 | ) | (85,492 | ) | ||||||||||
Bargain purchase gain | — | — | — | — | 44,633 | |||||||||||||||
Other (loss) gain | (3,774 | ) | 275 | 221 | (3,896 | ) | 2,936 | |||||||||||||
Operating (loss) profit before impairment losses | (38,693 | ) | (36,128 | ) | 14,277 | (101,724 | ) | 169,894 | ||||||||||||
Impairment losses | (174,018 | ) | (1,195 | ) | — | (175,353 | ) | — | ||||||||||||
Operating (loss) profit | (212,711 | ) | (37,323 | ) | 14,277 | (277,077 | ) | 169,894 | ||||||||||||
Net finance expense | (16,491 | ) | (15,047 | ) | (12,992 | ) | (45,361 | ) | (38,292 | ) | ||||||||||
Financial derivatives (loss) gain | 2,913 | (295 | ) | 388 | 3,882 | 1,455 | ||||||||||||||
Exchange differences | (5,083 | ) | 5,080 | (3,071 | ) | (1,482 | ) | (11,050 | ) | |||||||||||
(Loss) profit before tax | (231,372 | ) | (47,585 | ) | (1,398 | ) | (320,038 | ) | 122,007 | |||||||||||
Income tax benefit (expense) | 14,322 | 4,890 | (663 | ) | 27,422 | (28,350 | ) | |||||||||||||
(Loss) profit for the period from continuing operations | (217,050 | ) | (42,695 | ) | (2,061 | ) | (292,616 | ) | 93,657 | |||||||||||
Profit (loss) for the period from discontinued operations | 76,911 | (963 | ) | (855 | ) | 80,265 | 5,071 | |||||||||||||
(Loss) profit for the period | (140,139 | ) | (43,658 | ) | (2,916 | ) | (212,351 | ) | 98,728 | |||||||||||
Loss attributable to non-controlling interest | (385 | ) | 2,835 | 1,671 | 4,174 | 4,145 | ||||||||||||||
(Loss) profit attributable to the parent | $ | (140,524 | ) | $ | (40,823 | ) | $ | (1,245 | ) | $ | (208,177 | ) | $ | 102,873 | ||||||
EBITDA | $ | (183,120 | ) | $ | (7,119 | ) | $ | 43,864 | $ | (186,912 | ) | $ | 255,386 | |||||||
Adjusted EBITDA | $ | (7,210 | ) | $ | 5,035 | $ | 43,864 | $ | 1,152 | $ | 206,867 | |||||||||
Weighted average shares outstanding | ||||||||||||||||||||
Basic | 169,123 | 169,123 | 171,935 | 169,123 | 171,966 | |||||||||||||||
Diluted | 169,123 | 169,123 | 171,935 | 169,123 | 172,104 | |||||||||||||||
(Loss) profit per ordinary share | ||||||||||||||||||||
Basic | $ | (0.83 | ) | $ | (0.24 | ) | $ | (0.01 | ) | $ | (1.23 | ) | $ | 0.60 | ||||||
Diluted | $ | (0.83 | ) | $ | (0.24 | ) | $ | (0.01 | ) | $ | (1.23 | ) | $ | 0.60 |
* The amounts for prior periods have been restated to reflect the impact of the profit / (loss) from discontinued operations associated with the sale of the Company’s Spanish hydroelectric plants.
Unaudited Condensed Consolidated Statement of Financial Position
(in thousands of U.S. dollars)
September 30, | June 30, | December 31, | ||||||||
2019 | 2019 | 2018 | ||||||||
ASSETS | ||||||||||
Non-current assets | ||||||||||
Goodwill | $ | 29,702 | $ | 204,089 | $ | 202,848 | ||||
Other intangible assets | 63,980 | 62,778 | 51,822 | |||||||
Property, plant and equipment | 742,752 | 784,272 | 888,862 | |||||||
Other non-current financial assets | 3,381 | 20,042 | 70,343 | |||||||
Deferred tax assets | 50,214 | 22,915 | 14,589 | |||||||
Non-current receivables from related parties | 2,178 | 2,276 | 2,288 | |||||||
Other non-current assets | 1,780 | 9,746 | 10,486 | |||||||
Non-current restricted cash and cash equivalents | 10,889 | — | — | |||||||
Total non-current assets | 904,876 | 1,106,118 | 1,241,238 | |||||||
Current assets | ||||||||||
Inventories | 479,866 | 504,527 | 456,970 | |||||||
Trade and other receivables | 332,603 | 158,252 | 155,996 | |||||||
Current receivables from related parties | 2,839 | 3,000 | 14,226 | |||||||
Current income tax assets | 41,649 | 31,610 | 27,404 | |||||||
Other current financial assets | 1,660 | 7,840 | 2,523 | |||||||
Other current assets | 12,157 | 12,289 | 8,813 | |||||||
Cash and cash equivalents * | 177,154 | 187,673 | 216,647 | |||||||
Assets and disposal groups classified as held for sale | 8,507 | 97,862 | — | |||||||
Total current assets | 1,056,435 | 1,003,053 | 882,579 | |||||||
Total assets | $ | 1,961,311 | $ | 2,109,171 | $ | 2,123,817 | ||||
EQUITY AND LIABILITIES | ||||||||||
Equity | $ | 664,300 | $ | 816,080 | $ | 884,372 | ||||
Non-current liabilities | ||||||||||
Deferred income | 4,061 | 8,108 | 1,434 | |||||||
Provisions | 78,272 | 80,218 | 75,787 | |||||||
Bank borrowings | 130,622 | — | 132,821 | |||||||
Lease liabilities | 16,417 | 18,629 | 53,472 | |||||||
Debt instruments | 343,400 | 342,806 | 341,657 | |||||||
Other financial liabilities | 10,307 | 24,585 | 32,788 | |||||||
Other non-current liabilities | 29,982 | 25,246 | 25,030 | |||||||
Deferred tax liabilities | 82,192 | 64,520 | 77,379 | |||||||
Total non-current liabilities | 695,253 | 564,112 | 740,368 | |||||||
Current liabilities | ||||||||||
Provisions | 51,667 | 44,007 | 40,570 | |||||||
Bank borrowings | 130,272 | 172,890 | 8,191 | |||||||
Lease liabilities | 8,218 | 8,692 | 12,999 | |||||||
Debt instruments | 2,734 | 10,938 | 10,937 | |||||||
Other financial liabilities | 49,978 | 52,594 | 52,524 | |||||||
Payables to related parties | 9,160 | 9,884 | 11,128 | |||||||
Trade and other payables | 233,811 | 252,372 | 256,823 | |||||||
Current income tax liabilities | 11,173 | 1,766 | 2,335 | |||||||
Other current liabilities | 104,745 | 95,150 | 103,570 | |||||||
Liabilities associated with assets classified as held for sale | — | 80,686 | — | |||||||
Total current liabilities | 601,758 | 728,979 | 499,077 | |||||||
Total equity and liabilities | $ | 1,961,311 | $ | 2,109,171 | $ | 2,123,817 |
* Cash and cash equivalents include current restricted cash of
Unaudited Condensed Consolidated Statement of Cash Flows
(in thousands of U.S. dollars)
Quarter Ended | Quarter Ended | Quarter Ended | Nine Months Ended | Nine Months Ended | |||||||||||||||||
September 30, 2019 | June 30, 2019 | September 30, 2018 | September 30, 2019 | September 30, 2018 | |||||||||||||||||
Cash flows from operating activities: | |||||||||||||||||||||
(Loss) profit for the period | $ | (140,139 | ) | $ | (43,658 | ) | $ | (2,916 | ) | $ | (212,351 | ) | $ | 98,728 | |||||||
Adjustments to reconcile net (loss) profit to net cash used by operating activities: |
|||||||||||||||||||||
Income tax (benefit) expense | (14,489 | ) | (5,215 | ) | 573 | (26,408 | ) | 30,543 | |||||||||||||
Depreciation and amortization charges, operating allowances and write-downs |
29,591 | 31,327 | 30,750 | 92,995 | 89,075 | ||||||||||||||||
Net finance expense | 20,893 | 16,145 | 13,952 | 51,794 | 41,520 | ||||||||||||||||
Financial derivatives loss (gain) | (2,913 | ) | 295 | (388 | ) | (3,882 | ) | (1,455 | ) | ||||||||||||
Exchange differences | 5,083 | (5,080 | ) | 3,071 | 1,482 | 11,050 | |||||||||||||||
Impairment losses | 174,018 | 1,195 | — | 175,353 | — | ||||||||||||||||
Bargain purchase gain | — | — | — | — | (44,633 | ) | |||||||||||||||
Gain on disposal of discontinued operation | (80,729 | ) | — | — | (80,729 | ) | — | ||||||||||||||
Share-based compensation | 1,015 | 933 | 1,050 | 3,280 | 1,782 | ||||||||||||||||
Other adjustments | 3,774 | (275 | ) | (221 | ) | 3,896 | (2,936 | ) | |||||||||||||
Changes in operating assets and liabilities | |||||||||||||||||||||
(Increase) decrease in inventories | 5,953 | (46,950 | ) | (25,666 | ) | (40,962 | ) | (192,197 | ) | ||||||||||||
(Increase) decrease in trade receivables | 5,568 | (32,316 | ) | 6,224 | 1,623 | (13,546 | ) | ||||||||||||||
Increase (decrease) in trade payables | (10,693 | ) | 21,625 | (21,213 | ) | (12,035 | ) | 49,638 | |||||||||||||
Other | (59,689 | ) | 28,472 | 10,543 | (21,430 | ) | (32,410 | ) | |||||||||||||
Income taxes paid | (846 | ) | (540 | ) | (5,257 | ) | (3,066 | ) | (29,425 | ) | |||||||||||
Interest paid | (18,713 | ) | (3,341 | ) | (18,400 | ) | (40,562 | ) | (38,658 | ) | |||||||||||
Net cash (used) provided by operating activities | (82,316 | ) | (37,383 | ) | (7,898 | ) | (111,002 | ) | (32,924 | ) | |||||||||||
Cash flows from investing activities: | |||||||||||||||||||||
Interest and finance income received | 626 | 486 | 638 | 1,502 | 2,990 | ||||||||||||||||
Payments due to investments: | |||||||||||||||||||||
Acquisition of subsidiary | 9,088 | — | — | 9,088 | (20,379 | ) | |||||||||||||||
Other intangible assets | — | (50 | ) | (149 | ) | (184 | ) | (3,073 | ) | ||||||||||||
Property, plant and equipment | (6,269 | ) | (7,128 | ) | (25,696 | ) | (26,845 | ) | (78,005 | ) | |||||||||||
Other | — | (627 | ) | — | (627 | ) | (8 | ) | |||||||||||||
Disposals: | |||||||||||||||||||||
Disposal of subsidiaries | 171,058 | — | — | 171,058 | — | ||||||||||||||||
Other non-current assets | — | — | — | — | 12,734 | ||||||||||||||||
Other | 19 | 1,638 | 947 | 3,416 | 6,861 | ||||||||||||||||
Net cash used by investing activities | 174,522 | (5,681 | ) | (24,260 | ) | 157,408 | (78,880 | ) | |||||||||||||
Cash flows from financing activities: | |||||||||||||||||||||
Dividends paid | — | — | (10,321 | ) | — | (20,642 | ) | ||||||||||||||
Payment for debt issuance costs | (2,093 | ) | — | — | (2,798 | ) | (4,476 | ) | |||||||||||||
Repayment of hydro leases | (55,352 | ) | — | — | (55,352 | ) | — | ||||||||||||||
Repayment of other financial liabilities | — | — | — | — | (33,096 | ) | |||||||||||||||
Increase/(decrease) in bank borrowings: | |||||||||||||||||||||
Borrowings | — | 39,649 | 25,286 | 71,499 | 245,318 | ||||||||||||||||
Payments | (21,038 | ) | (18,252 | ) | — | (60,101 | ) | (106,514 | ) | ||||||||||||
Proceeds from stock option exercises | — | — | — | — | 240 | ||||||||||||||||
Other amounts paid due to financing activities | (9,324 | ) | (7,236 | ) | (3,067 | ) | (22,268 | ) | (10,702 | ) | |||||||||||
Payments to acquire or redeem own shares | — | — | (3,502 | ) | — | (3,502 | ) | ||||||||||||||
Net cash provided (used) by financing activities | (87,807 | ) | 14,161 | 8,396 | (69,020 | ) | 66,626 | ||||||||||||||
Total net cash flows for the period | 4,399 | (28,903 | ) | (23,762 | ) | (22,614 | ) | (45,178 | ) | ||||||||||||
Beginning balance of cash and cash equivalents | 188,045 | 216,627 | 155,984 | 216,647 | 184,472 | ||||||||||||||||
Exchange differences on cash and cash equivalents in foreign currencies |
(4,401 | ) | 321 | (551 | ) | (5,990 | ) | (7,623 | ) | ||||||||||||
Ending balance of cash and cash equivalents | $ | 188,043 | $ | 188,045 | $ | 131,671 | $ | 188,043 | $ | 131,671 | |||||||||||
Cash from continuing operations | 177,154 | 187,673 | 131,671 | 177,154 | 131,671 | ||||||||||||||||
Non-current restricted cash and cash equivalents | 10,889 | — | — | 10,889 | — | ||||||||||||||||
Cash held for sale | — | 372 | — | — | — | ||||||||||||||||
Cash and restricted cash in the statement of financial position | $ | 188,043 | $ | 188,045 | $ | 131,671 | $ | 188,043 | $ | 131,671 |
Adjusted EBITDA
Quarter Ended | Quarter Ended | Quarter Ended | Nine Months Ended | Nine Months Ended | ||||||||||||||||
September 30, 2019 | June 30, 2019 | September 30, 2018 | September 30, 2019 | September 30, 2018 | ||||||||||||||||
(Loss) profit attributable to the parent | $ | (140,524 | ) | $ | (40,823 | ) | $ | (1,245 | ) | $ | (208,177 | ) | $ | 102,873 | ||||||
Loss (profit) for the period from discontinued operations | (76,911 | ) | 963 | 855 | (80,265 | ) | (5,071 | ) | ||||||||||||
Loss attributable to non-controlling interest | 385 | (2,835 | ) | (1,671 | ) | (4,174 | ) | (4,145 | ) | |||||||||||
Income tax (benefit) expense | (14,322 | ) | (4,890 | ) | 663 | (27,422 | ) | 28,350 | ||||||||||||
Net finance expense | 16,491 | 15,047 | 12,992 | 45,361 | 38,292 | |||||||||||||||
Financial derivatives loss (gain) | (2,913 | ) | 295 | (388 | ) | (3,882 | ) | (1,455 | ) | |||||||||||
Exchange differences | 5,083 | (5,080 | ) | 3,071 | 1,482 | 11,050 | ||||||||||||||
Depreciation and amortization charges, operating allowances and write-downs | 29,591 | 30,204 | 29,587 | 90,165 | 85,492 | |||||||||||||||
EBITDA | (183,120 | ) | (7,119 | ) | 43,864 | (186,912 | ) | 255,386 | ||||||||||||
Impairment | 174,008 | — | — | 174,008 | — | |||||||||||||||
Revaluation of biological assets | 1,080 | — | — | 1,080 | — | |||||||||||||||
Contract termination costs | — | 9,260 | — | 9,260 | — | |||||||||||||||
Restructuring and termination costs | — | 2,894 | — | 2,894 | — | |||||||||||||||
Loss on disposal of non-core businesses | 822 | — | — | 822 | — | |||||||||||||||
Bargain purchase gain | — | — | — | — | (44,633 | ) | ||||||||||||||
Share-based compensation | — | — | — | — | (3,886 | ) | ||||||||||||||
Adjusted EBITDA | $ | (7,210 | ) | $ | 5,035 | $ | 43,864 | $ | 1,152 | $ | 206,867 |
Adjusted profit attributable to
Quarter Ended | Quarter Ended | Quarter Ended | Nine Months Ended | Nine Months Ended | ||||||||||||||||
September 30, 2019 | June 30, 2019 | September 30, 2018 | September 30, 2019 | September 30, 2018 | ||||||||||||||||
(Loss) profit attributable to the parent | $ | (140,524 | ) | $ | (40,823 | ) | $ | (1,245 | ) | $ | (208,177 | ) | $ | 102,873 | ||||||
Tax rate adjustment | 59,717 | 10,337 | 1,110 | 74,990 | (10,692 | ) | ||||||||||||||
Impairment | 118,325 | — | — | 118,325 | — | |||||||||||||||
Revaluation of biological assets | 734 | — | — | 734 | — | |||||||||||||||
Contract termination costs | — | 6,297 | — | 6,297 | — | |||||||||||||||
Restructuring and termination costs | — | 1,968 | — | 1,968 | — | |||||||||||||||
Profit on disposal of non-core businesses | (54,337 | ) | — | — | (54,337 | ) | — | |||||||||||||
Bargain purchase gain | — | — | — | — | (30,350 | ) | ||||||||||||||
Share-based compensation | — | — | — | — | (2,642 | ) | ||||||||||||||
Adjusted (loss) profit attributable to the parent | $ | (16,085 | ) | $ | (22,221 | ) | $ | (135 | ) | $ | (60,200 | ) | $ | 59,189 |
Adjusted diluted profit per share:
Quarter Ended | Quarter Ended | Quarter Ended | Nine Months Ended | Nine Months Ended | ||||||||||||||||
September 30, 2019 | June 30, 2019 | September 30, 2018 | September 30, 2019 | September 30, 2018 | ||||||||||||||||
Diluted (loss) profit per ordinary share | $ | (0.83 | ) | $ | (0.24 | ) | $ | (0.01 | ) | $ | (1.23 | ) | $ | 0.60 | ||||||
Tax rate adjustment | 0.35 | 0.06 | 0.01 | 0.44 | (0.06 | ) | ||||||||||||||
Impairment | 0.70 | — | — | 0.70 | — | |||||||||||||||
Revaluation of biological assets | 0.00 | — | — | 0.00 | — | |||||||||||||||
Contract termination costs | — | 0.04 | — | 0.04 | — | |||||||||||||||
Restructuring and termination costs | — | 0.01 | — | 0.01 | — | |||||||||||||||
Loss on disposal of non-core businesses | (0.32 | ) | — | — | (0.32 | ) | — | |||||||||||||
Bargain purchase gain | — | — | — | — | (0.18 | ) | ||||||||||||||
Share-based compensation | — | — | — | — | (0.02 | ) | ||||||||||||||
Adjusted diluted (loss) profit per ordinary share | $ | (0.10 | ) | $ | (0.13 | ) | $ | (0.00 | ) | $ | (0.36 | ) | $ | 0.34 |
Source: Ferroglobe PLC